1. Home
  2. CDLR vs AUPH Comparison

CDLR vs AUPH Comparison

Compare CDLR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

SELL

Current Price

$21.67

Market Cap

2.1B

Sector

N/A

ML Signal

SELL

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

SELL

Current Price

$16.52

Market Cap

2.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CDLR
AUPH
Founded
2008
1993
Country
Denmark
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
CDLR
AUPH
Price
$21.67
$16.52
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $17.86
AVG Volume (30 Days)
72.7K
★ 772.2K
Earning Date
11-23-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 5075.00
EPS
N/A
★ 0.53
Revenue
N/A
★ $283,055,000.00
Revenue This Year
$54.35
$15.83
Revenue Next Year
$37.14
$21.30
P/E Ratio
★ $7.39
$31.55
Revenue Growth
N/A
★ 20.38
52 Week Low
$15.37
$11.39
52 Week High
$30.01
$19.25

Technical Indicators

Market Signals
Indicator
CDLR
AUPH
Relative Strength Index (RSI) 38.54 54.37
Support Level $20.96 $15.61
Resistance Level $22.21 $17.02
Average True Range (ATR) 0.49 0.42
MACD -0.05 0.04
Stochastic Oscillator 47.73 59.18

Price Performance

Historical Comparison
CDLR
AUPH

About CDLR Cadeler AS

Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: